Question on F&A for company without NICRA (R21) Caroline Leopold (28 Jul 2014 09:10 EST)
Re: Question on F&A for company without NICRA (R21) Moise, Jessica (28 Jul 2014 10:21 EST)
Re: Question on F&A for company without NICRA (R21) Caroline Leopold (28 Jul 2014 12:44 EST)
Re: Question on F&A for company without NICRA (R21) Lawrence Waxler (28 Jul 2014 10:44 EST)
Re: Question on F&A for company without NICRA (R21) Michael Spires (28 Jul 2014 12:03 EST)
Re: Question on F&A for company without NICRA (R21) Caroline Leopold (28 Jul 2014 12:59 EST)

Re: Question on F&A for company without NICRA (R21) Lawrence Waxler 28 Jul 2014 10:44 EST

Caroline,

Under the new OMNI Circular, the Federal government is allowing a 10% rate for any agency with no negotiated rate.

If the company wants anything difference/higher, given that the new regs are not final from each agencies perspective and won't be until December, you should probably contact the NIH program officer to get a read on what they will allow or what process they might suggest.

Larry

~~~~~~~~~~~~~~~~~~~~~~~
Larry Waxler, Director
Office of Sponsored Programs
University of Southern Maine
1 Chamberlain Avenue
P.O. Box 9300
Portland, ME  04104-9300
Telephone: 207-780-4413
Telefax: 207-780-4927

>>> Caroline Leopold <xxxxxx@LEOPOLDGRANTS.COM> 7/28/2014 10:10 AM >>>
I am providing pre-award consulting with a digital health company who has
partnered with a university PI to submit an R21 for NIH's October deadline.

The company's role is substantial and wants to be a consortium partner.
Multiple staff at the company will serve as key personnel and are allocated
effort in the budget. However, the company does not have a negotiated
indirect cost rate agreement (NICRA).

I am more familiar with the F&A rules of SBIR/STTR in regards to companies.

I have reviewed the NIH FAQ at:

http://oalm.od.nih.gov/IndirectCostsFAQ#processstart

It appears as if the company can add a reasonable indirect rate into the
NIH grant application and then negotiate with the NIH if there is a strong
possibility of an award.

I fear that I am overly optimistic and misreading the guidelines. That is
why I am turning the experts here at RESADM-L.

Any guidance on or offlist would be greatly appreciated. Thank you so much.

Best Regards,
Caroline

--
Caroline Leopold, GPC
Grants Consultant and Medical Writer
Leopold Grants Consulting
xxxxxx@leopoldgrants.com
LinkedIn Profile <http://www.linkedin.com/in/cleopold/>

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.healthresearch.org (click on the
 "LISTSERV" link in the upper right corner)

 A link directly to helpful tips:  http://tinyurl.com/resadm-l-help
======================================================================

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.healthresearch.org (click on the
 "LISTSERV" link in the upper right corner)

 A link directly to helpful tips:  http://tinyurl.com/resadm-l-help
======================================================================